Incyte Corporation (INCY)
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing.
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Incyte Stock Eyes Worst Day Since 2018 After Trial Results
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Incyte's skin disease drug meets main goal in two late-stage studies
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
Reevaluating Incyte Corporation After Earnings (Technical Analysis)
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below its 30-week EMA, with short-term bearish momentum but long-term bullish momentum, making it a cautious buy. Volume analysis shows neutral institutional activity, and relative strength indicates INCY is trading on par with the S&P 500 since May 2024.
Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates. The stock has declined due to 2025 guidance coming below expectations. Despite slowing sales growth for Jakafi and Opzelura, Incyte's pipeline with four product launches in 2025 and potential $1B incremental revenue by 2029 bodes well for continued growth. The company has a strong track record of revenue growth and a robust pipeline targeting over 10 high-impact product launches by 2030.
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
